avidin + yttrium-90-DOTA-biotin (Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori")

Avidin-biotin-DOTA-90Y is an investigational, two-component pretargeted radionuclide therapy (PRT) system designed for the treatment of nonpalpable (occult) breast cancer. The therapy utilizes a sequential intralesional administration strategy: first, native avidin is injected at the tumor site (following vacuum-assisted biopsy), where it serves as an interstitial molecular anchor due to its high retention in the tissue. Subsequently, yttrium-90-labeled DOTA-biotin (90Y-DOTA-biotin) is administered locally. The extremely high affinity between avidin and biotin ensures that the radioactive payload binds tightly to the anchored avidin, delivering targeted beta radiation directly to the malignant lesion while minimizing systemic exposure. This approach is being evaluated in the Phase 1 ARTHE trial to assess safety and anti-tumor activity in patients with occult infiltrating breast cancer.

Other names

avidin-biotin-dota-90Yavidin-biotin-dota90Yavidin-biotin-dota 90Y90Y-DOTA-biotinyttrium-90-labeled DOTA-biotinyttrium90-labeled DOTA-biotinyttrium 90-labeled DOTA-biotin